- Home
- GWH vs ABP Comparison
GWH vs ABP Comparison
Compare GWH & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- ABP
- Stock Information
- Founded
- GWH 2011
- ABP 2004
- Country
- GWH United States
- ABP United States
- Employees
- GWH N/A
- ABP N/A
- Industry
- GWH Industrial Machinery/Components
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- ABP Health Care
- Exchange
- GWH Nasdaq
- ABP Nasdaq
- Market Cap
- GWH 17.1M
- ABP 15.5M
- IPO Year
- GWH N/A
- ABP N/A
- Fundamental
- Price
- GWH $1.20
- ABP $0.21
- Analyst Decision
- GWH Hold
- ABP Strong Buy
- Analyst Count
- GWH 5
- ABP 1
- Target Price
- GWH $2.10
- ABP $4.00
- AVG Volume (30 Days)
- GWH 2.2M
- ABP 5.6M
- Earning Date
- GWH 08-13-2025
- ABP 08-18-2025
- Dividend Yield
- GWH N/A
- ABP N/A
- EPS Growth
- GWH N/A
- ABP N/A
- EPS
- GWH N/A
- ABP N/A
- Revenue
- GWH $4,155,999.00
- ABP $183,000.00
- Revenue This Year
- GWH $179.38
- ABP N/A
- Revenue Next Year
- GWH $175.77
- ABP N/A
- P/E Ratio
- GWH N/A
- ABP N/A
- Revenue Growth
- GWH N/A
- ABP 88.66
- 52 Week Low
- GWH $0.76
- ABP $0.15
- 52 Week High
- GWH $14.10
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- GWH 44.07
- ABP N/A
- Support Level
- GWH $0.95
- ABP N/A
- Resistance Level
- GWH $1.44
- ABP N/A
- Average True Range (ATR)
- GWH 0.12
- ABP 0.00
- MACD
- GWH 0.05
- ABP 0.00
- Stochastic Oscillator
- GWH 50.00
- ABP 0.00
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.